Reports Q1 revenue $1.01B, consensus $992.27M. James Foster, Chair, President and Chief Executive Officer, said, “Our first-quarter performance was a solid first step towards achieving our financial outlook for the year, particularly in our Manufacturing segment. Our DSA segment saw improved proposal activity and cancellations in the first quarter, and while encouraging, our outlook for the year remains appropriately measured. It will take time for this proposal activity and stronger biotech funding to translate into new DSA bookings and revenue generation; however, these trends are consistent with our expectations that demand will improve later this year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- CRL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Charles River announces rare disease gene therapy collaboration with Axovia
- Charles River to perform plasmid production for Ship of Theseus
- Charles River extends gene therapy manufacturing alliance with NUS Medicine
- Charles River price target raised to $290 from $200 at Argus